KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Patient experience with familial chylomicronemia syndrome before and after olezarsen treatment: Qualitative interviews with clinical trial participants. PMID 40713231 · J Clin Lipidol · 2025 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Sample Size for Enriched Biomarker Designs With Measurement Error for Time-to-Event Outcomes. PMID 40711765 · Pharm Stat · 2025 The record describes a methodological article on sample size calculation for enriched biomarker designs in oncology trials. It is not an original report of a Phase III randomized trial's results with a drug-containing intervention and a time-to-event efficacy endpoint. The article is eligible for exclusion based on its type (methodology/design paper) and lack of original trial result reporting.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Oligometastatic head and neck cancer: Navigating patient trajectories and broader implications. PMID 40706555 · Cancer Radiother · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Cost-effectiveness analysis of sintilimab additional to chemoradiotherapy in high-risk locoregionally advanced nasopharyngeal carcinoma. PMID 40703356 · Front Pharmacol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Time-in-Range Analysis of Responses after Intravitreal Dexamethasone Therapy in Eyes with Diabetic Macular Edema. PMID 40688490 · Ophthalmol Sci · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Comparison of anlotinib combined with docetaxel versus single docetaxel as second-line treatment beside radiotherapy for advanced non-small cell lung cancer: Efficacy and safety. PMID 40679002 · Pak J Pharm Sci · 2025 The record describes a randomized trial in oncology with a drug intervention and a time-to-event endpoint (PFS). However, the phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata (title, abstract, publication types, MeSH). The metadata indicates 'needs_review' with 'phase3_evidence_unclear'. Per the adjudication rules, the phase must be explicitly established; it cannot be inferred or assumed. Therefore, the required criterion of phase3_or_definitive cannot be confirmed.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of opioid-free anesthesia in short-term recovery following laparoscopic-assisted colorectal tumor resection: a randomized trial. PMID 40672749 · Front Oncol · 2025 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
In vitro 3D drug sensitivity testing for patient-derived tumor-like cell clusters and whole-exome sequencing to personalize postoperative treatment: A study protocol for a multicenter randomized controlled trial. PMID 40658653 · PLoS One · 2025 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Biweekly CAPOX versus triweekly CAPOX in the adjuvant therapy of post-surgery CRC: A randomized controlled trial. PMID 40644418 · PLoS One · 2025 The study meets most criteria: it is an oncology, human, randomized trial with a drug intervention and reports a time-to-event efficacy endpoint (3-year DFS) with HR. However, the phase is not explicitly stated in the provided metadata as Phase III/IIIb or Phase II/III (only 'randomized controlled trial' is noted). Additionally, the primary endpoint is safety (thrombocytopenia), while the key secondary endpoint is the efficacy endpoint (DFS). To be eligible, the trial must be explicitly Phase III/IIIb or Phase II/III and the time-to-event endpoint must be the primary or key secondary endpoint of a definitive trial. Without explicit phase confirmation, eligibility cannot be established.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of aerobic exercise on body composition and exerkines in colorectal cancer survivors. PMID 40642656 · Front Sports Act Living · 2025 The record describes a randomized trial of aerobic exercise in colorectal cancer survivors with immune biomarker endpoints. It is eligible for oncology and human criteria, but it is excluded because it lacks a drug intervention and a time-to-event efficacy endpoint. The study is not a Phase III/IIIb or Phase II/III trial and does not report Kaplan-Meier or HR data for OS/PFS/DFS.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A double-blind, placebo-controlled, randomized, multi-centre, phase III study of MLC901 (NeuroAiDTMII) for the treatment of cognitive impairment after mild traumatic brain injury. PMID 40638707 · PLoS One · 2025 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The PD COMM Process Evaluation: Describing Interventions and Implementation in a UK Pragmatic Randomised Controlled Trial of Speech and Language Therapy for People With Parkinson's-Related Dysarthria. PMID 40637984 · Int J Lang Commun Disord · 2025 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Neoadjuvant chemotherapy with or without metformin in early-stage or locally advanced (non-metastatic) triple negative breast cancer-an open-label phase 2 randomized controlled trial. PMID 40636683 · Front Oncol · 2025 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Electroacupuncture Prevent and Treat Perioperative Cognitive Impairment in Elderly Patients Undergoing Hip Surgery: A Protocol for a Randomized Controlled Trial. PMID 40606589 · J Pain Res · 2025 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Lebrikizumab Improved Itch Symptoms and Reduced Itch Interference on Sleep over 52 Weeks in Patients with Moderate-to-Severe Atopic Dermatitis in Two Phase 3 Trials. PMID 40602386 · Dermatology · 2025 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of SmofKabiven® Versus Hospital-Compounded All-in-One Parenteral Nutrition in Chinese Patients Undergoing Gastrointestinal Surgery: A Multicenter, Randomized, Active-Controlled, Phase III Trial. PMID 40598717 · Nutr Cancer · 2025 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose-ranging, double-blind, randomized controlled trial. PMID 40586377 · Headache · 2025 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Self-reported health and depression among EIRA cohort: a moderated mediation model of sex and perceived social support. PMID 40584072 · Front Psychol · 2025 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Attractive targeted sugar baits for malaria control in western Kenya (ATSB-Kenya) - Effect of ATSBs on epidemiologic and entomologic indicators: A Phase III, open-label, cluster-randomised, controlled trial. PMID 40570028 · PLOS Glob Public Health · 2025 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance. PMID 40554538 · PLoS One · 2025 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-Term Symptomatic and Functional Remission with Paliperidone Palmitate 6-Monthly Treatment in Schizophrenia: A 3-Year Post-Hoc Analysis. PMID 40548350 · Neuropsychiatr Dis Treat · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A digitally enabled home-based wound care program using the PEDALs model: a mixed-methods study protocol. PMID 40547473 · Front Public Health · 2025 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab. PMID 40546817 · Ther Adv Hematol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Use of TDCS with proprioceptive exercises to improve gait and balance in visually impaired children and preadolescents: a protocol for randomized clinical trial study. PMID 40538416 · Front Rehabil Sci · 2025 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Povidone-iodine nasal spray (Nasodine®) for the common cold: a randomized, controlled, double-blind, Phase III clinical trial. PMID 40538402 · Front Med (Lausanne) · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effectiveness of mucoactives (carbocisteine and hypertonic saline) in addition to usual airway clearance management with usual airway clearance management alone in acute respiratory failure (MARCH): study protocol for a multi-centre 2x2 factorial, randomised, controlled, open-label, Phase 3, pragmatic, clinical and cost-effectiveness trial with internal pilot. PMID 40519627 · NIHR Open Res · 2025 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effects of Topical Capsaicin for Chemotherapy-Induced Peripheral Neuropathy (CIPN) Prophylaxis in Oxaliplatin-Treated Cancer Patients: A Double-Blind Randomized Clinical Trial. PMID 40519580 · Adv Biomed Res · 2025 The study is a randomized, double-blind, placebo-controlled trial in cancer patients evaluating a drug (capsaicin) for prevention of chemotherapy-induced peripheral neuropathy. The primary efficacy endpoint is neuropathy grade (ordinal) and symptom severity, which is a toxicity/side-effect outcome, not a time-to-event efficacy endpoint such as OS, PFS, DFS, etc. Therefore, it does not meet the requirement for a Kaplan-Meier or time-to-event primary/key secondary endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of Peer Education on Early Breast Cancer Detection, Health Responsibility, Health Beliefs, Knowledge, and Practices Among University Students. PMID 40518814 · Public Health Nurs · 2025 The study is a randomized controlled trial on early breast cancer detection and education, but it lacks a drug intervention, does not specify a Phase III design, and does not report time-to-event efficacy endpoints like OS or PFS.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Preoperative Radiotherapy Does Not Increase the Risk for Early Complications Following Surgery for Oral Cancer: A Study on Data From the Randomized ARTSCAN 2 Trial. PMID 40515490 · J Otolaryngol Head Neck Surg · 2025 The study is an RCT in oncology, but it lacks a drug-containing intervention (radiotherapy is non-drug) and does not report a primary/key secondary time-to-event efficacy endpoint; therefore, it does not meet all eligibility criteria for the cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of perioperative ONS combined with intestinal microecology in patients with colorectal cancer: a randomized clinical trial. PMID 40497027 · Front Nutr · 2025 The record is a randomized trial in human oncology patients with a drug-containing intervention (ONS + probiotic) and reports primary results. However, it lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) as required by the cohort definition. The endpoints are nutritional status, inflammation, and intestinal function recovery. Additionally, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Adoptive cellular immunotherapy combined with chemotherapy versus chemotherapy alone in Chinese patients with metastatic colorectal cancer: a cost-effectiveness analysis to inform drug pricing. PMID 40496606 · Front Oncol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effect of Faricimab versus Aflibercept on Hyperreflective Foci in Patients with Diabetic Macular Edema from the YOSEMITE/RHINE Trials. PMID 40496217 · Ophthalmol Sci · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Clinical study outcomes in IgA nephropathy: A systematic literature review and narrative synthesis. PMID 40493692 · PLoS One · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Comparing Liposomal Bupivacaine and Ropivacaine in Serratus Anterior Plane Block for Thoracoscopic Lobectomy: A Randomized Controlled Trial. PMID 40491528 · Drug Des Devel Ther · 2025 The study is a randomized controlled trial in oncology patients, but it lacks a reported phase, its primary endpoint is a pain score (not time-to-event), and the intervention is a local anesthetic for postoperative pain management, not an anticancer drug intervention for efficacy against the malignant neoplasm.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Designing a multi-arm, multi-stage platform trial for venous leg ulceration - Venous leg ulcers: management and eradication, the VEIN platform study.: Designing a platform/adaptive trial for venous leg ulcers (VLU) - The VEIN platform. PMID 40487135 · NIHR Open Res · 2025 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Optimizing muscle mass and function in advanced lung cancer patients: randomized, double-blind, placebo-controlled trial protocol using High Eicosapentaenoic acid and PROtein (HEPRO) to modulate epigenetics, reduce toxicity and improve gut microbiota. PMID 40487055 · PeerJ · 2025 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Validation and pilot feasibility study of a novel screener to assess diet, lifestyle and mental health in people living with and beyond cancer: Study protocols. PMID 40472046 · PLoS One · 2025 The record is a protocol for a validation and pilot feasibility study, not a formal report of results from a definitive randomized trial. It does not meet the criteria for Phase III/IIIb or Phase II/III, drug intervention, or time-to-event efficacy endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Positioning Guselkumab in The Treatment Algorithm of Patients with Crohn's Disease. PMID 40470513 · Biologics · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Lanadelumab for prevention of attacks of non-histaminergic normal C1 inhibitor angioedema: results from the randomized, double-blind CASPIAN Study and CASPIAN open-label extension. PMID 40469312 · Front Immunol · 2025 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
GPT-4 generates accurate and readable patient education materials aligned with current oncological guidelines: A randomized assessment. PMID 40465696 · PLoS One · 2025 This is a randomized trial assessing AI-generated patient education materials for oncological guidelines. While it involves oncology and human subjects, it is not a drug intervention trial, does not report Phase III/IIIb or Phase II/III results, and lacks a primary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, etc.) or Kaplan-Meier/HR analysis. The study's primary outcomes are readability, accuracy, completeness, and clarity scores.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Anxiolysis for laceration repair in children: study protocol for an open-label multicenter adaptive trial (ALICE). PMID 40465577 · PLoS One · 2025 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Preclinical NCI-MPACT: prospective modeling of the mutation-based NCI-MPACT clinical trial therapeutic strategy in patient-derived xenograft models. PMID 40458731 · Front Oncol · 2025 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Single-centre, single-blind, randomized, active-controlled phase-3 non-inferiority study to investigate the safety and efficacy of the cardioplegic solution Cardioplexol™. PMID 40458598 · Front Cardiovasc Med · 2025 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
12-Month Outcomes of a Prospective Randomized Trial Investigating Effects of IVIG on Top of rATG Versus rATG Alone in Pre-Sensitized Kidney Transplant Recipients: The INHIBIT Study. PMID 40458542 · Transpl Int · 2025 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The Immunomodulatory Effect of Vitamin B12 in Pernicious Anemia: A Systematic Review. PMID 40458194 · Oxid Med Cell Longev · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Thalidomide confers therapeutic benefit in beta thalassemia patients by enhancing hemoglobin and hematopoietic gene expression: A non-randomized clinical trial. PMID 40446669 · Blood Cells Mol Dis · 2025 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Association of predicted lean body mass and fat mass with prognosis in patients with heart failure preserved ejection fraction. PMID 40446077 · PLoS One · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Genomewide association analysis on green tea chemoprevention of colorectal adenoma: the importance of SLCO1A2 variants. PMID 40433816 · Pharmacogenomics · 2025 The record is a post-hoc pharmacogenetic analysis of the MIRACLE trial. It does not meet key inclusion criteria: the intervention is a dietary supplement (green tea extract), not a conventional drug; the primary endpoint is adenoma recurrence (binary), not a time-to-event; and the analysis is a subgroup/biomarker study, not the primary efficacy report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Supplementation of multienzyme with acidifier alleviates the antinutritional effects of a high soybean meal diet for nursery pigs. PMID 40433456 · Front Vet Sci · 2025 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Comparison between the safety of the HPV vaccine versus placebo: a systematic review and meta-analysis of randomized clinical trials. PMID 40425051 · J Pediatr (Rio J) · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -